An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer

Researchers investigated FcR-expressing immune effector cells in HER2+ and triple-negative breast cancers, including neoadjuvant chemotherapy–resistant disease. FcγRIIIa expression, FcγRIIIa+ NK cells, and classically activated macrophages correlated with improved anti-HER2 antibody efficacy.